Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab (DT) in patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) resistant to AR pathway inhibitors (ARPI). Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hotte, Sebastien
  • Khalaf, Daniel Joseph
  • Ernst, D Scott
  • Ferrario, Cristiano
  • Ong, Michael
  • Kolinsky, Michael Paul
  • Salim, Muhammad
  • Nappi, Lucia
  • Mukherjee, Som
  • Winquist, Eric
  • Rose, April AN
  • Chi, Kim N
  • Potvin, Kylea R
  • Seymour, Lesley K
  • Kwan, Edmond Michael
  • Smoragiewicz, Martin
  • Ghaedi, Hamid
  • Tu, Wei
  • Jafri, Mariam
  • Wyatt, Alexander William

publication date

  • June 2025